Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).
Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.
In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.
"The durable responses observed with this drug are notable in the context of the safety profile and route of oral, at-home administration, and will offer an important new option for physicians as we care for patients with relapsed/refractory follicular lymphoma."
“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."
Efficacy analyses by cell of origin and by MYC and BCL2 double expression status showed a trend toward improved outcomes of patients treated on the polatuzumab vedotin-containing arm regardless of cell of origin or MYC and BCL2 doubkle expression status.
Treatment with SGX301 led to statistically significant responses in patients with cutaneous T-cell lymphoma, according to preliminary top-line results from the pivotal phase III FLASH trial released by Soligenix.
The FDA has placed a partial clinical hold on the phase I trial of ACTR707 in combination with rituximab in patients with relapsed/refractory B-cell lymphoma from Unum Therapeutics, following the submission of a safety report from the company. The FDA notified Unum of the hold verbally on March 4. Unum Therapeutics acknowledged the partial clinical hold in filings with the Securities and Exchange commission.